Tesamorelin

Tesamorelin 10 & 20 mg (GHRH Analogue)

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone, commonly known as GHRH. Researchers study its interaction with the pituitary gland and the body’s natural growth-hormone signalling system.

Research Areas

Laboratory and clinical research examines how Tesamorelin influences growth-hormone release and downstream insulin-like growth factor-1 activity. Tesamorelin Canada research also includes endocrine function, metabolic regulation, body-composition pathways and visceral adipose tissue.

Additional areas of interest include lipid metabolism, glucose regulation, energy balance and metabolic signalling. Unlike HGH, Tesamorelin does not act as a direct replacement for growth hormone. Instead, it interacts with GHRH receptors and stimulates growth-hormone release in experimental models, making it useful for comparative endocrine research.

Researchers may also compare Tesamorelin with HGH-191AA and Ipamorelin. HGH-191AA provides growth hormone directly, whereas Tesamorelin acts through GHRH receptors and Ipamorelin acts through growth-hormone secretagogue receptors. These distinct mechanisms make the compounds relevant to comparative research involving the GH/IGF-1 axis.

For researchers seeking Tesamorelin in Canada, this product provides a versatile model for metabolic, pituitary, body-composition and growth-hormone research.

Further reading: Compare the mechanisms in our guide to Tesamorelin, Ipamorelin and CJC-1295.

Product Specifications

• Form: Lyophilized powder
• Scientific / alternate name: TH9507
• Vial sizes: 10 mg, 20 mg

For laboratory and research purposes only. Not intended for human or veterinary use, diagnosis, treatment or consumption.